Corporate Report

The report presents a strong FY2015 financial result, with consolidated revenue of ¥160,284 million and operating profit of ¥30,507 million. It describes continued expansion of OPDIVO and broader oncology capabilities as key business highlights. Environmental reporting records a 17.2% reduction in CO2 emissions from production and research sites compared with FY2005, alongside ongoing energy-saving initiatives. The report also reproduces a limited independent assurance report covering its Energy-derived CO2 Emissions.